| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| TRIOBIOTICS PHARMA Aktie jetzt für 0€ handeln |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 37,800 | -1,00 % | Glyphosat-Showdown: UBS bleibt bullish - 44%-Chance bei Bayer | Bayer steht vor wichtigen Entscheidungen im Glyphosat-Streit. Die UBS bleibt dennoch bei Kaufen und sieht 44 Prozent Kurspotenzial. Doch ein neues Worst-Case-Szenario droht. Bayer steht vor wichtigen... ► Artikel lesen | |
| CDT EQUITY | 1,495 | -0,33 % | CDT Equity's Sarborg stake valued at $127.5M after fundraise | ||
| MERCK KGAA | 132,80 | -0,15 % | JEFFERIES stuft MERCK KGAA auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Merck KGaA auf "Hold" mit einem Kursziel von 129 Euro belassen. Das Segment Life Science sei ein wesentlicher, mit geringeren... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 15,860 | -0,19 % | Generate:Biomedicines: Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update | SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance
Clinical trial sites activated for GB-4362 (MMAE neutralizer); first... ► Artikel lesen | |
| NOVO NORDISK | 40,670 | +1,33 % | Abnehmpille stark gefragt: Drei Millionen Rezepte in 22 Wochen: Warum Analysten bei Novo Nordisk nachlegen | © Foto: Christian Schultz/dpaDie Wegovy-Pille verkauft sich schneller als gedacht. Analysten der Privatbank Berenberg reagieren mit einer deutlichen Kurszielanhebung und sehen für Novo Nordisk noch... ► Artikel lesen | |
| KARDIGAN | 22,820 | +0,22 % | Kardigan, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Kardigan, Inc. (Nasdaq: KARD) ("Kardigan"), a clinical-stage precision therapeutics company developing medicines that target the root... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 63,41 | -0,13 % | Bright Minds Biosciences Announces Closing of US$175 Million Public Offering | NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") today closed its recently announced public offering of 1,945... ► Artikel lesen | |
| LB PHARMACEUTICALS | 29,850 | -0,07 % | LB Pharmaceuticals stock rating maintained at buy by H.C. Wainwright | ||
| ELI LILLY | 969,70 | +0,34 % | Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk | ||
| AQUESTIVE THERAPEUTICS | 4,700 | -0,42 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Reaffirms guidance to resubmit Anaphylm (dibutepinephrine) sublingual film NDA in Q3 2026Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 32,680 | -0,12 % | Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO (miltefosine) | IMPAVIDO is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania speciesLeishmaniasis is a rare but potentially life-threatening... ► Artikel lesen | |
| SEAPORT THERAPEUTICS | 17,920 | -0,39 % | Seaport Therapeutics Prices Upsized IPO Of 14.16 Mln Shares At $18 Each | WASHINGTON (dpa-AFX) - Seaport Therapeutics, Inc. (SPTX) said it has priced its upsized initial public offering of 14.16 shares at $18 per share, at the top of the target range. The company... ► Artikel lesen | |
| PFIZER | 21,930 | -0,09 % | Pfizer-Finanzchef geht im August | NEW YORK (dpa-AFX) - Pfizer steht vor einem Wechsel im Finanzressort. Wie der US-Pharmakonzern am Donnerstag in New York mitteilte, wird Finanzvorstand Dave Denton sein Amt zum 15. August niederlegen... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 14,090 | +0,64 % | Kazia Therapeutics Limited: Kazia Therapeutics Appoints James Levine as Chief Financial Officer | SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company... ► Artikel lesen | |
| JOURNEY MEDICAL | 6,430 | 0,00 % | Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased... ► Artikel lesen |